Quell Therapeutics is a major global biopharmaceutical company that is dedicated to delivering innovative and life-changing therapies for patients suffering from autoimmune and inflammatory diseases. They also specialize in preventing rejection in organ transplantation. Quell's approach is based on modular engineered Tregs, which are cells that help regulate the immune system.

The company was founded in 2019 through a partnership with six renowned immunological experts from prestigious institutions such as King's College London and University College London. Led by Iain McGill, an experienced pharmaceutical executive, Quell has a strong leadership team with expertise in immunology and transplantation. Quell focuses on developing transformative therapies that are highly valued by physicians, patients, and payors.

They prioritize keeping the patient at the center of all their efforts. The company is dedicated to building a strong culture that drives decision-making and actions, ensuring they achieve their goals and live their values. With a commitment to being a leading player in the field of immune dysregulation, Quell is poised to deliver truly innovative therapies that have the potential to revolutionize patient care